The Involvement of Arginase and Nitric Oxide Synthase in Breast Cancer Development: Arginase and NO Synthase as Therapeutic Targets in Cancer

الملخص EN

It is well established that, during development of malignancies, metabolic changes occur, including alterations of enzyme activities and isoenzyme expression.

Arginase and nitric oxide (NO) synthase (NOS) are two of those enzymes considered to be involved in tumorigenesis.

The goal of this article was to study the involvement of arginase and NOS in the development of different stages of breast cancer.

Our results have shown that human serum arginase activity and NO (resp., and NOS activity) and polyamines quantities increased in parallel with cancer stage progression and decreased after neoadjuvant chemotherapy.

For breast cancer, the only isoenzyme of arginase expressed in serum before and after chemotherapy was in a cationic form.

The data of Lineweaver-Burk plot with a Km value of 2 mM was calculated, which is characteristic for human liver type isoform of arginase.

During electrophoresis at pH 8.9, the enzyme exhibited high electrophoretic mobility and was detected near the anode.

The presented results demonstrated that arginase in human serum with breast cancer and after chemotherapy is not polymorphic.

We suggest that arginase and NOS inhibition has antitumor effects on cancer development, as it can inhibit polyamines and NO levels, a precursor of cancer cell proliferation, metastasis, and tumor angiogenesis.